These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients. Escobar A; López M; Serrano A; Ramirez M; Pérez C; Aguirre A; González R; Alfaro J; Larrondo M; Fodor M; Ferrada C; Salazar-Onfray F Clin Exp Immunol; 2005 Dec; 142(3):555-68. PubMed ID: 16297169 [TBL] [Abstract][Full Text] [Related]
5. A phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10 -1082 promoter genotype as predictor of disease progression. von Euw EM; Barrio MM; Furman D; Levy EM; Bianchini M; Peguillet I; Lantz O; Vellice A; Kohan A; Chacón M; Yee C; Wainstok R; Mordoh J J Transl Med; 2008 Jan; 6():6. PubMed ID: 18221542 [TBL] [Abstract][Full Text] [Related]
6. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. Salcedo M; Bercovici N; Taylor R; Vereecken P; Massicard S; Duriau D; Vernel-Pauillac F; Boyer A; Baron-Bodo V; Mallard E; Bartholeyns J; Goxe B; Latour N; Leroy S; Prigent D; Martiat P; Sales F; Laporte M; Bruyns C; Romet-Lemonne JL; Abastado JP; Lehmann F; Velu T Cancer Immunol Immunother; 2006 Jul; 55(7):819-29. PubMed ID: 16187085 [TBL] [Abstract][Full Text] [Related]
7. Dendritic cell-based vaccine in advanced melanoma: update of clinical outcome. Ridolfi L; Petrini M; Fiammenghi L; Granato AM; Ancarani V; Pancisi E; Brolli C; Selva M; Scarpi E; Valmorri L; Nicoletti SV; Guidoboni M; Riccobon A; Ridolfi R Melanoma Res; 2011 Dec; 21(6):524-9. PubMed ID: 21909041 [TBL] [Abstract][Full Text] [Related]
8. Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial. Trepiakas R; Berntsen A; Hadrup SR; Bjørn J; Geertsen PF; Straten PT; Andersen MH; Pedersen AE; Soleimani A; Lorentzen T; Johansen JS; Svane IM Cytotherapy; 2010 Oct; 12(6):721-34. PubMed ID: 20429791 [TBL] [Abstract][Full Text] [Related]
9. Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma. Dillman RO; Cornforth AN; Depriest C; McClay EF; Amatruda TT; de Leon C; Ellis RE; Mayorga C; Carbonell D; Cubellis JM J Immunother; 2012 Oct; 35(8):641-9. PubMed ID: 22996370 [TBL] [Abstract][Full Text] [Related]
10. Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma. Hersey P; Menzies SW; Halliday GM; Nguyen T; Farrelly ML; DeSilva C; Lett M Cancer Immunol Immunother; 2004 Feb; 53(2):125-34. PubMed ID: 14600790 [TBL] [Abstract][Full Text] [Related]
11. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells. López MN; Pereda C; Segal G; Muñoz L; Aguilera R; González FE; Escobar A; Ginesta A; Reyes D; González R; Mendoza-Naranjo A; Larrondo M; Compán A; Ferrada C; Salazar-Onfray F J Clin Oncol; 2009 Feb; 27(6):945-52. PubMed ID: 19139436 [TBL] [Abstract][Full Text] [Related]
12. Dendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent of Disease at the Time of Treatment. Dillman RO; McClay EF; Barth NM; Amatruda TT; Schwartzberg LS; Mahdavi K; de Leon C; Ellis RE; DePriest C Cancer Biother Radiopharm; 2015 Jun; 30(5):187-94. PubMed ID: 26083950 [TBL] [Abstract][Full Text] [Related]
13. Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma. Redman BG; Chang AE; Whitfield J; Esper P; Jiang G; Braun T; Roessler B; Mulé JJ J Immunother; 2008; 31(6):591-8. PubMed ID: 18528294 [TBL] [Abstract][Full Text] [Related]
14. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. O'Rourke MG; Johnson M; Lanagan C; See J; Yang J; Bell JR; Slater GJ; Kerr BM; Crowe B; Purdie DM; Elliott SL; Ellem KA; Schmidt CW Cancer Immunol Immunother; 2003 Jun; 52(6):387-95. PubMed ID: 12682787 [TBL] [Abstract][Full Text] [Related]
15. Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate. Vilella R; Benítez D; Milà J; Lozano M; Vilana R; Pomes J; Tomas X; Costa J; Vilalta A; Malvehy J; Puig S; Mellado B; Martí R; Castel T Cancer Immunol Immunother; 2004 Jul; 53(7):651-8. PubMed ID: 14999431 [TBL] [Abstract][Full Text] [Related]
16. A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma. Sarivalasis A; Boudousquié C; Balint K; Stevenson BJ; Gannon PO; Iancu EM; Rossier L; Martin Lluesma S; Mathevet P; Sempoux C; Coukos G; Dafni U; Harari A; Bassani-Sternberg M; Kandalaft LE J Transl Med; 2019 Nov; 17(1):391. PubMed ID: 31771601 [TBL] [Abstract][Full Text] [Related]
17. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial. Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV Trials; 2018 May; 19(1):293. PubMed ID: 29801515 [TBL] [Abstract][Full Text] [Related]
18. Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2. Nagayama H; Sato K; Morishita M; Uchimaru K; Oyaizu N; Inazawa T; Yamasaki T; Enomoto M; Nakaoka T; Nakamura T; Maekawa T; Yamamoto A; Shimada S; Saida T; Kawakami Y; Asano S; Tani K; Takahashi TA; Yamashita N Melanoma Res; 2003 Oct; 13(5):521-30. PubMed ID: 14512794 [TBL] [Abstract][Full Text] [Related]
19. Dendritic cell vaccination in human melanoma: relationships between clinical effects and vaccine parameters. Nakai N; Hartmann G; Kishimoto S; Katoh N Pigment Cell Melanoma Res; 2010 Oct; 23(5):607-19. PubMed ID: 20579307 [TBL] [Abstract][Full Text] [Related]
20. Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma. Wilgenhof S; Van Nuffel AM; Corthals J; Heirman C; Tuyaerts S; Benteyn D; De Coninck A; Van Riet I; Verfaillie G; Vandeloo J; Bonehill A; Thielemans K; Neyns B J Immunother; 2011 Jun; 34(5):448-56. PubMed ID: 21577140 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]